# Deutsche Schmerzgesellschaft

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/deutsche-schmerzgesellschaft/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 56 |
| Citations | 41,782 |
| City | Berlin |
| Country | DE |
| Description | Deutsche Schmerzgesellschaft is a research organisation in Berlin, DE. OpenAlex records 1,130 works and 41,782 citations for it. 330 researchers list it as their most recent affiliation. |
| Homepage | http://www.dgss.org/startseite/ |
| OpenAlex ID | https://openalex.org/I4210114523 |
| Researchers | 330 |
| ROR ID | https://ror.org/01qgd7x17 |
| Type | other |
| Works | 1,130 |

## University papers

- [Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-or-everolimus-for-advanced-renal-cell-carcinoma/)
- [Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/renal-cell-carcinoma-esmo-clinical-practice-guideline-for-diagnosis-treatment/)
- [Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial](https://scholariq.org/papers/quality-of-life-in-patients-with-advanced-renal-cell-carcinoma-given-nivolumab/)
- [Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial](https://scholariq.org/papers/adjuvant-nivolumab-plus-ipilimumab-versus-placebo-for-localised-renal-cell/)
- [Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-sunitinib-in-first-line-treatment-of/)
- [Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-sunitinib-as-first-line-treatment-of/)

## University top topics

Showing 8 of 20.

- [Clinical practice guidelines implementation](https://scholariq.org/topics/clinical-practice-guidelines-implementation/)
- [Health and Medical Studies](https://scholariq.org/topics/health-and-medical-studies/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Medical Practices and Rehabilitation](https://scholariq.org/topics/medical-practices-and-rehabilitation/)
- [Economic and Financial Impacts of Cancer](https://scholariq.org/topics/economic-and-financial-impacts-of-cancer/)
- [Cancer survivorship and care](https://scholariq.org/topics/cancer-survivorship-and-care/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Pain Management and Opioid Use](https://scholariq.org/topics/pain-management-and-opioid-use/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.